Introduction: Ovarian cancer is the leading cause of death from gynecologic cancers, in
fact,> 80% of cases are diagnosed as advanced-stage disease associated with a high …

Gynecological cancers (GCs) are often diagnosed at advanced stages, limiting the efficacy
of available therapeutic options. Thus, there remains an urgent and unmet need for …

Background: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human
epididymis secretory protein 4 (HE4) and CA125 successfully classified patients as …

BACKGROUND Human epididymis protein 4 (HE4), a precursor of human epididymis
protein, has been proposed as a tumor marker for ovarian cancer. We evaluated HE4 in …

The aim of this study is to evaluate a new tumour marker, HE4, in comparison with CA 125
and the Risk of Ovarian Malignancy Algorithm (ROMA) in healthy women and in patients …

Background: The study is aimed at evaluating the performance of the predictive model
ROMA (Risk of Ovarian Malignancy Algorithm), which utilizes the combination of human …

OBJECTIVE: About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at
advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally …

Background: To date, no good marker for screening or disease monitoring of endometrial
cancer (EC) is available. The aims of this study were to investigate HE4 gene, protein …

OBJECTIVE: The quality of first surgery is one of the most important prognostic factors in
ovarian cancer patients. Pre-surgical distinction of benign and malignant pelvic mass plays …

Background microRNAs (miRNAs) stably exist in circulating blood encapsulated in
extracellular vesicles such as exosomes; therefore, serum miRNAs have the potential to …